Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Drug Information » FDA Approved Drugs » 1997
Medical Areas: Pulmonary/Respiratory Diseases | Family Medicine

View By:YearCompanyConditionsTherapeutic AreasDrug Names

Raxar (grepafloxacin)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company: GlaxoSmithKline
Approval Status: Approved November 1997
Treatment Area: chronic bronchitis

General Information

Raxar (grepafloxacin) has been approved for mild to moderate cases of acute bacterial exacerbations of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis; for community-acquired pneumonia caused by the same bacteria as well as Mycoplasma pneumoniae; for uncomplicated gonorrhea caused by Neissaria gonorrhoeae; and for nongonococcal urethritis and cervicitis caused by Chlymidia trachomatis.

Raxar tablets are contraindicated in patients with hepatic failure.

Side Effects

Adverse reactions for a multiple-dose regimen of Raxar 600 mg include a 15.8% incidence of nausea, 17.8% of taste perversion, 5.7% of vomiting, 5.4% of dizziness, 4.2% of diarrhea, and 2.2% of constipation.